慢性粒细胞白血病耐药机制及治疗方法的新进展
New progress in drug resistant mechanism and treatment of chronic myeloid leukemia
慢性粒细胞白血病（chronic myeloid leukemia, CML）是一种多能造血干细胞来源的恶性增殖性疾病。酪氨酸激酶抑制剂（tyrosine kinase inhibitors, TKIs）在临床上的广泛应用极大改善了CML患者的预后，然而耐药的出现降低了TKIs的疗效。本文着重对TKIs耐药产生的机制、针对耐药现象该如何应对以及新药研发的最近成果等方面进行论述。
hronic myeloid leukemia (CML) is a malignant proliferative disease of multiple hematopoietic stem cells. The wide use of tyrosine kinase inhibitors (TKIs) has greatly improved the prognosis of patients with CML, however, the emergence of drug resistance has reduced the efficacy of TKIs. This article focuses on the mechanism of TKIs resistance, how to deal with the drug resistance phenomenon, as well as the recent achievements in the development of new drugs and other aspects of the discussion.
钱文斌、何玮
医药卫生理论医学现状、医学发展肿瘤学
慢性粒细胞白血病酪氨酸激酶抑制剂耐药
chronic myeloid leukemiatyrosine kinase inhibitordrug resistance
钱文斌,何玮.慢性粒细胞白血病耐药机制及治疗方法的新进展[EB/OL].(2016-05-26)[2025-06-28].http://www.paper.edu.cn/releasepaper/content/201605-1321.点此复制
评论